SEC Form 10-Q filed by OmniAb Inc.

11/12/24 4:59:53 PM ET

$OABI

Biotechnology: Commercial Physical & Biological Resarch

Health Care

Get the next $OABI alert in real time by email

oabi-20240930

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________________________________________________________________________

FORM 10-Q

________________________________________________________________________________________

☒

Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 2024

☐

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Transition Period From ______ to ______.

Commission File Number: 001-40720

OMNIAB, INC.

(Exact name of registrant as specified in its charter)

Delaware

98-1584818

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

5980 Horton Street, Suite 600

Emeryville

94608

(Address of principal executive offices)

(Zip Code)

(510) 250-7800

(Registrant's Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of Each Exchange on Which Registered
Common stock, $0.0001 par value per share	OABI	The Nasdaq Global Market
Warrants to purchase common stock	OABIW	The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

☐

Accelerated Filer

☐

Non-Accelerated Filer

☒

Smaller Reporting Company

☒

Emerging Growth Company

☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 5, 2024, the registrant had 121,012,583 shares of common stock outstanding.

TABLE OF CONTENTS


PART I. FINANCIAL INFORMATION
	ITEM 1. Condensed Consolidated Financial Statements (unaudited)	3
	Condensed Consolidated Balance Sheets	3
	Condensed Consolidated Statements of Operations	4
	Condensed Consolidated Statements of Comprehensive Loss	5
	Condensed Consolidated Statements of Stockholders' Equity	6
	Condensed Consolidated Statements of Cash Flows	7
	Notes to Condensed Consolidated Financial Statements	8
	ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	28
	ITEM 3. Quantitative and Qualitative Disclosures about Market Risk	34
	ITEM 4. Controls and Procedures	35
PART II. OTHER INFORMATION
	ITEM 1. Legal Proceedings	36
	ITEM 1A. Risk Factors	36
	ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds	36
	ITEM 3. Defaults Upon Senior Securities	36
	ITEM 4. Mine Safety Disclosures	36
	ITEM 5. Other Information	36
	ITEM 6. Exhibits	37
	SIGNATURES	38

Part I – Financial Information

Item 1. Condensed Consolidated Financial Statements

OMNIAB, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)


	September 30, 2024		December 31, 2023
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	27,236	$	16,358
Short-term investments	32,145		70,625
Accounts receivable, net	3,495		3,844
Prepaid expenses and other current assets	3,733		4,074
Total current assets	66,609		94,901
Intangible assets, net	144,119		155,467
Goodwill	83,979		83,979
Property and equipment, net	16,333		18,249
Operating lease right-of-use assets	18,333		19,884
Restricted cash	560		560
Other long-term assets	1,621		2,185
Total assets	$	331,554	$	375,225
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	2,187	$	4,411
Accrued expenses and other current liabilities	5,446		7,068
Current contingent liabilities	510		1,303
Current deferred revenue	2,508		6,848
Current operating lease liabilities	3,751		3,486
Total current liabilities	14,402		23,116
Long-term contingent liabilities	1,111		3,203
Deferred income taxes, net	4,131		11,354
Long-term operating lease liabilities	20,088		22,075
Long-term deferred revenue	41		862
Other long-term liabilities	53		30
Total liabilities	39,826		60,640
Stockholders' equity:
Preferred stock, $0.0001 par value; 100,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding at September 30, 2024 and December 31, 2023	—		—
Common stock, $0.0001 par value; 1,000,000,000 shares authorized at September 30, 2024 and December 31, 2023; 120,222,547 and 116,859,468 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	12		12
Additional paid-in capital	379,999		353,890
Accumulated other comprehensive income	49		50
Accumulated deficit	(88,332)		(39,367)
Total stockholders’ equity	291,728		314,585
Total liabilities and stockholders’ equity	$	331,554	$	375,225

See accompanying notes to unaudited condensed consolidated financial statements.

OMNIAB, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except per share data)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Revenue:
License and milestone revenue	$	1,375	$	2,010	$	5,216	$	18,986
Service revenue	2,479		3,016		9,416		9,425
Royalty revenue	318		451		955		931
Total revenue	4,172		5,477		15,587		29,342
Operating expenses:
Research and development	13,318		13,867		41,804		41,759
General and administrative	7,079		8,511		23,381		25,444
Amortization of intangibles	3,393		3,398		11,348		10,147
Other operating expense (income), net	146		16		(2,324)		205
Total operating expenses	23,936		25,792		74,209		77,555
Loss from operations	(19,764)		(20,315)		(58,622)		(48,213)
Other income (expense), net:
Interest income	691		1,265		2,451		3,874
Other income (expense), net	(8)		8		(17)		4
Total other income (expense), net	683		1,273		2,434		3,878
Loss before income taxes	(19,081)		(19,042)		(56,188)		(44,335)
Income tax benefit	2,708		3,304		7,223		7,769
Net loss	$	(16,373)	$	(15,738)	$	(48,965)	$	(36,566)

Net loss per share, basic and diluted	$	(0.16)	$	(0.16)	$	(0.48)	$	(0.37)

Weighted-average shares outstanding, basic and diluted	102,393		99,905		101,538		99,521

See accompanying notes to unaudited condensed consolidated financial statements.

OMNIAB, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited)

(in thousands)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Net loss	$	(16,373)	$	(15,738)	$	(48,965)	$	(36,566)
Unrealized net gain (loss) on available-for-sale securities	74		—		(1)		(58)
Comprehensive loss	$	(16,299)	$	(15,738)	$	(48,966)	$	(36,624)

See accompanying notes to unaudited condensed consolidated financial statements.

OMNIAB, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

(in thousands, except share data)


	Common Stock			Additional paid-in capital		Accumulated other comprehensive income (loss)		Retained earnings (Accumulated deficit)		Total stockholders’ equity
	Shares	Amount
Balance at January 1, 2024	116,859,468	$	12	$	353,890	$	50	$	(39,367)	$	314,585
Net loss	—	—		—		—		(18,961)		(18,961)
Share-based compensation	—	—		5,695		—		—		5,695
Issuance of common stock under employee stock compensation plans, net of tax	529,321	—		141		—		—		141
Unrealized net loss on available-for-sale securities	—	—		—		(67)		—		(67)
Balance at March 31, 2024	117,388,789	$	12	$	359,726	$	(17)	$	(58,328)	$	301,393
Net loss	—	—		—		—		(13,631)		(13,631)
Share-based compensation	—	—		5,383		—		—		5,383
Issuance of common stock under employee stock compensation plans, net of tax	767,537	—		1,044		—		—		1,044
Unrealized net loss on available-for-sale securities	—	—		—		(8)		—		(8)
Balance at June 30, 2024	118,156,326	$	12	$	366,153	$	(25)	$	(71,959)	$	294,181
Net loss	—	—		—		—		(16,373)		(16,373)
Share-based compensation	—	—		5,305		—		—		5,305
Issuance of common stock under employee stock compensation plans, net of tax	36,243	—		106		—		—		106
Issuance of common stock under ATM facility, net of commissions and issuance costs	2,029,978	—		8,435		—		—		8,435
Unrealized net gain on available-for-sale securities	—	—		—		74		—		74
Balance at September 30, 2024	120,222,547	$	12	$	379,999	$	49	$	(88,332)	$	291,728

Balance at January 1, 2023	115,218,229	$	12	$	330,100	$	9	$	11,252	$	341,373
Net loss	—	—		—		—		(6,100)		(6,100)
Share-based compensation	—	—		6,055		—		—		6,055
Issuance of common stock under employee stock compensation plans, net of tax	366,291	—		(524)		—		—		(524)
Unrealized net loss on available-for-sale securities	—	—		—		(2)		—		(2)
Balance at March 31, 2023	115,584,520	$	12	$	335,631	$	7	$	5,152	$	340,802
Net loss	—	—		—		—		(14,728)		(14,728)
Share-based compensation	—	—		6,529		—		—		6,529
Issuance of common stock under employee stock compensation plans, net of tax	567,196	—		1,259		—		—		1,259
Unrealized net loss on available-for-sale securities	—	—		—		(56)		—		(56)
Balance at June 30, 2023	116,151,716	$	12	$	343,419	$	(49)	$	(9,576)	$	333,806
Net loss	—	—		—		—		(15,738)		(15,738)
Share-based compensation	—	—		6,310		—		—		6,310
Issuance of common stock under employee stock compensation plans, net of tax	80,283	—		171		—		—		171
Balance at September 30, 2023	116,231,999	$	12	$	349,900	$	(49)	$	(25,314)	$	324,549

See accompanying notes to unaudited condensed consolidated financial statements.

OMNIAB, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)


	Nine Months Ended September 30,
	2024		2023
Operating activities:
Net loss	$	(48,965)	$	(36,566)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	15,977		14,563
Share-based compensation	16,383		18,894
Amortization of discounts on short-term investments, net	(1,285)		(2,651)
Deferred income taxes, net	(7,223)		(7,467)
Change in estimated fair value of contingent liabilities	(2,410)		(275)
Other	524		90
Changes in operating assets and liabilities, net:
Accounts receivable, net	1,263		24,911
Prepaid expenses and other current assets	341		2,312
Other long-term assets	564		(134)
Accounts payable, accrued expenses, and other liabilities	(3,186)		1,446
Operating lease liabilities	(1,722)		380
Deferred revenue	(6,053)		(4,035)
Net cash (used in) provided by operating activities	(35,792)		11,468
Investing activities:
Purchases of short-term investments	(25,669)		(86,885)
Proceeds from the maturity of short-term investments	63,500		66,250
Purchases of property and equipment	(1,829)		(1,537)
Payments to contingent liabilities holders	(400)		(3,640)
Proceeds from sale of short-term investments	1,897		2,706
Net cash provided by (used in) investing activities	37,499		(23,106)
Financing activities:
Payments to contingent liabilities holders	(75)		—
Proceeds from issuance of common stock from stock plans	2,251		990
Taxes paid related to net share settlement of equity awards	(960)		(914)
Payment of transaction costs	(525)		(472)
Proceeds from issuance of common stock under ATM facility, net of commissions	8,480		—
Net cash provided by (used in) financing activities	9,171		(396)
Net change in cash, cash equivalents and restricted cash	10,878		(12,034)
Cash, cash equivalents and restricted cash at beginning of period	16,918		33,839
Cash, cash equivalents and restricted cash at end of period	$	27,796	$	21,805
Supplemental cash flow information:
Deferred revenue recorded in accounts receivable	$	892	$	831
Supplemental non-cash investing and financing activities:
Purchase of fixed assets recorded in accounts payable	$	—	$	28
Intangible additions recorded in contingent liabilities	$	—	$	1,376

See accompanying notes to unaudited condensed consolidated financial statements.

OMNIAB, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Organization and Basis of Presentation

Description of Business

OmniAb, Inc. (“OmniAb” or the “Company”, formerly known as Avista Public Acquisition Corp. II (“APAC”)) is a biotechnology company that licenses cutting edge discovery research technology to the pharmaceutical and biotech industries and academic institutions to enable the discovery of next-generation therapeutics. The Company’s technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. At the heart of the OmniAb platform is something the Company calls Biological Intelligence™, which powers the immune systems of its proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. The Company primarily derives revenue from license fees for technology access, milestones from partnered programs and service revenue from research programs.

Business Combination

On November 1, 2022 (the “Closing Date”), the Company, Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Ligand”), OmniAb Operations, Inc., a Delaware corporation and wholly-owned subsidiary of Ligand (“Legacy OmniAb”, formerly known as OmniAb, Inc.), and Orwell Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of APAC (“Merger Sub”), consummated the transactions contemplated by the Agreement and Plan of Merger (the “Merger Agreement”), dated as of March 23, 2022 (the “Business Combination”). See Note 3 – Business Combination for further details.

Basis of Presentation

The Company’s accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as included in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The financial information for the three and nine months ended September 30, 2024 and 2023, is unaudited but includes all normal and recurring adjustments unless indicated otherwise, which the Company considered necessary for fair presentation of its condensed consolidated statements of operations and comprehensive loss. Certain prior period amounts in the condensed consolidated financial statements have been reclassified to conform to the current period presentation.

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and accounts within the Company have been eliminated.

Liquidity and Capital Resources

The Company expects to continue to incur losses as it invests in research and development activities to improve its technology platform, market and sell its technologies to existing and new partners, add operational, financial and management information systems and personnel to support its operations and incur ongoing costs associated with operating as a public company. The Company’s ability to continue its operations is dependent upon its ability to generate cash flows from operations and potentially obtain additional capital in the future. The Company believes its existing cash, cash equivalents and short-term investments and the cash it expects to generate from operations will provide it the flexibility needed to meet operating, investing, and financing needs and support operations through at least the next 12 months.

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

Emerging Growth Company

OmniAb qualifies as an emerging growth company as defined in Section 2(a) of the Securities Act of 1933, as amended, (“Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”).

Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. OmniAb has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, OmniAb, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of OmniAb’s financial statements with another public company, which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period, difficult because of the potential differences in accounting standards used.

2. Summary of Significant Accounting Policies

Use of Estimates

The preparation of these condensed consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.

Cash, Cash Equivalents, and Restricted Cash

Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less when purchased. Cash and cash equivalents generally consist of bank deposits, money market funds as well as U.S. government and agency securities. The following table provides a reconciliation of the components of cash, cash equivalents and restricted cash reported in the condensed consolidated balance sheets to the total of the amount presented in the condensed consolidated statements of cash flows:


(in thousands)	September 30, 2024		December 31, 2023
Cash and cash equivalents	$	27,236	$	16,358
Restricted cash	560		560
Total cash, cash equivalents and restricted cash presented in the condensed consolidated statements of cash flows	$	27,796	$	16,918

Restricted cash relates to deposits for the Company’s property leases. The restriction will lapse when the related leases expire.

Short-term Investments

Short-term investments generally consist of commercial paper, corporate debt securities, asset-backed securities and U.S. government and agency securities. The Company classifies short-term investments as “available-for-sale” as the sale of such investments may be required prior to maturity to implement management strategies. Therefore, the Company has classified all investments with maturity dates beyond three months at the date of purchase as current assets in the accompanying condensed consolidated balance sheets based upon its ability and intent to use the investments to satisfy the liquidity needs of current operations. Any premium or discount arising at purchase is amortized and/or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. Investments are reported at their estimated fair value. Unrealized gains and losses are included in accumulated other comprehensive income (loss) as a component of stockholders’ equity until realized.

Accounts Receivable

Accounts receivable represents the amounts billed to the Company’s partners that are due unconditionally for revenue it has earned. The Company establishes an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance requires an estimation based upon historical loss experienced and adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include delinquency trends, aging behavior of receivables, credit and liquidity quality indicators for industry groups, customer classes or individual customers and the current and expected future economic and market conditions.

Property and Equipment

Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense.


Asset						Estimated Useful Life
Lab and office equipment						4 - 7 years
Computer hardware						3 - 5 years
Leasehold improvements						Shorter of the useful life or remaining lease term
Computer software						Shorter of 3 years or useful life of asset

Acquisitions

The Company first determines whether a set of assets acquired constitutes a business and should be accounted for as a business combination. If the assets acquired are not a business, the Company accounts for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting which requires the Company to use significant estimates and assumptions, including fair value estimates, as of the business combination date and to refine those estimates as necessary during the measurement period (defined as the period, not to exceed one year, in which the Company may adjust the provisional amounts recognized).

Under the acquisition method of accounting, the Company recognizes separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash is remeasured to estimated fair value at each reporting period with the change in fair value recorded in the statement of operations. Costs that the Company incurs to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and the Company charges them to general and administrative expense as they are incurred.

The Company measures goodwill as of the acquisition date as the excess of consideration transferred, which is also measured at fair value, over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed.

Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, the Company reports provisional amounts in its financial statements. During the measurement period, the Company adjusts the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and the Company records those adjustments to its financial statements in the period of change, if any.

Under the acquisition method of accounting for business combinations, if the Company identifies changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and the Company records the offset to goodwill. The Company records all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense.

Goodwill, Intangible Assets and Other Long-Lived Assets

Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, the Company assesses qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than the carrying amount, including goodwill. The Company operates in one reporting unit. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, cost factors, the overall financial performance, and events affecting the reporting unit. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the quantitative assessment. The Company will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, the Company generally uses a combination of market approach based on OmniAb and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. The Company’s cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. The Company performs its annual assessment for goodwill impairment during the fourth quarter each year. No impairment indicators were noted in any periods presented in the condensed consolidated financial statements under the qualitative assessment.

The Company’s identifiable intangible assets are composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. Identifiable intangible assets with finite lives are generally amortized on a straight-line basis over the assets’ respective estimated useful life. The Company regularly performs reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, the Company estimates the fair value of the assets and records an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset. Other than an impairment of the Company’s finite-lived intangible assets related to certain legacy assets from Ligand’s acquisition of Ab Initio Biotherapeutics, Inc. (“Ab Initio”) in July 2019, as further described in Note 7 – Goodwill and Intangible Assets, Net, the Company did not identify indicators of impairment for its other intangible and long-lived assets at September 30, 2024 and December 31, 2023.

Public, Private Placement, Forward Purchase and Backstop Common Stock Warrants

The Company assumed 7,666,667 warrants originally issued in APAC’s initial public offering (the “Public Warrants”) and 8,233,333 warrants issued in a private placement that closed concurrently with APAC’s initial public offering, (the “Private Placement Warrants”) in the Business Combination. Additionally, as further discussed in Note 3 – Business Combination, pursuant to the Amended and Restated Forward Purchase Agreement, dated as of March 23, 2022 (the “A&R FPA”), on the Closing Date, the Company issued 1,666,667 warrants in the Forward Purchase (the “Forward Purchase Warrants”) and 1,445,489 warrants in the Redemption Backstop (the “Backstop Warrants”). The Public, Private Placement, Forward Purchase and Backstop Warrants entitle the holder to purchase one share of the Company’s common stock at an exercise price of $11.50 per share.

The Public Warrants are publicly traded and are exercisable for cash unless certain conditions occur, such as the failure to have an effective registration statement related to the shares issuable upon exercise or redemption by the Company under certain conditions, at which time the warrants may be cashless exercised at the option of the Company. The Private Placement Warrants have terms and provisions that are identical to the Public Warrants except that the Private Placement Warrants were not transferable, assignable or salable until 30 days after the completion of the Business Combination. The Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the Public Warrants. The Forward Purchase Warrants and the Backstop Warrants have the same terms as the Private Placement Warrants.

The Company evaluated the Public, Private Placement, Forward Purchase and Backstop Warrants under ASC 815-40, Derivatives and Hedging-Contracts in Entity’s Own Equity (“ASC 815-40”), and concluded they meet the criteria for equity classification as they are considered to be indexed to the Company’s own stock.

Revenue Recognition

The Company applies the following five-step model in accordance with ASC 606, Revenue from Contracts with Customers, in order to determine revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

The Company’s revenue is typically derived from license agreements with its partners and consists of: (i) upfront or annual payments for technology access (license revenue), (ii) payments for the performance of research services (service revenue), (iii) downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones (milestone revenue) and (iv) royalties on net sales from partners’ product sales (royalty revenue).

License fees are recognized when (or as) control of a performance obligation is transferred to the customer. When combined performance obligations contain a promised license and related services or other promises, management judgment is required to determine whether revenue is recognized at a point in time or over time. If a license for technology access is deemed to be the predominant promise in a performance obligation, the Company first determines the nature of the license, whether functional or symbolic intellectual property, to conclude whether revenue recognition as of a point in time or over time is most appropriate. The determination of functional or symbolic intellectual property requires an assessment of whether the customer is able to benefit from the license in its current condition, or if the utility of the license is dependent on or influenced by the Company’s ongoing activities.

The Company recognizes service revenue for contracted R&D services performed for partners over time. The Company measures its progress using an input method based on the effort it expends or costs it incurs relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that it multiplies by the transaction price to determine the amount of revenue recognized each period. This approach requires the Company to make estimates and use judgment. If estimates or judgments change over the course of the collaboration, they may affect the timing and amount of revenue recognized in current and future periods.

The Company includes contingent milestone based payments in the estimated transaction price when there is a basis to reasonably estimate the amount of the payment and it is probable of being achieved. These estimates are based on historical experience, anticipated results and its best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for licenses of intellectual property. Because of the risk that products in development with partners will not reach development based milestones or receive regulatory approval, the Company generally recognizes any contingent payments that would be due to it upon or after achievement of the development milestone or regulatory approval.

Deferred Revenue

Depending on the terms of the arrangement, the Company may also defer a portion of the consideration received if it needs to satisfy a future obligation.

The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the condensed consolidated balance sheets. The Company generally receives payment at the point it satisfies its obligation or soon after. Any fees billed in advance of being earned are recorded as deferred revenue. During each of the three and nine months ended September 30, 2024, the amount recognized as revenue that was previously deferred at June 30, 2024 and December 31, 2023 was $1.4 million and $6.1 million, respectively. During each of the three and nine months ended September 30, 2023, the amount recognized as revenue that was previously deferred at June 30, 2023 and December 31, 2022 was $2.3 million and $4.8 million, respectively.

Disaggregation of Revenue

The disaggregated revenue categories are presented on the face of the condensed consolidated statements of operations.

Research and Development Expenses

Research and development expenses consist of material, equipment, facilities and labor costs of scientific staff who are working pursuant to collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for research programs including in-licensing costs, and costs incurred by other research and development service vendors. The Company expenses these costs as they are incurred. When the Company makes payments for research and development services prior to the services being rendered, it records those amounts as prepaid expenses on its condensed consolidated balance sheets and it expenses them as the services are provided.

Share-Based Compensation

The Company recognizes share-based compensation expense based on the estimated fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration forfeitures as they occur. The fair value of restricted stock units (“RSUs”) is determined by the closing market price of the Company’s common stock on the date of grant. Performance-based restricted stock units (“PRSUs”) generally represent the right to receive a certain number of shares of common stock based on the achievement of the Company’s corporate performance or market goals and continued employment during the vesting period. Share-based compensation expense for market-based PRSUs is measured using the Monte-Carlo valuation model and is not adjusted for the achievement, or lack thereof, of market conditions.

The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock options granted and stock purchases under the ESPP. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate.

The Company measures and recognizes compensation expense for shares to be issued under its employee stock purchase plan based on an estimated grant date fair value recognized on a straight-line basis over the offering period.

Income Taxes

The Company provides for income taxes under the asset and liability method prescribed by the ASC Topic 740, Income Taxes (“Topic 740”). Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates in effect when the differences are expected to reverse. If necessary, deferred tax assets are reduced by a valuation allowance to reflect the uncertainty associated with their ultimate realization.

The Company accounts for uncertain tax positions recognized in the condensed consolidated financial statements in accordance with the provisions of Topic 740 by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could affect its income tax provision in future periods. Interest and penalty charges, if any, related to unrecognized tax benefits would be classified as a provision for income tax in the condensed consolidated statements of operations.

Income (Loss) Per Share

Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income (loss) per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period.

Comprehensive Income (Loss)

Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale debt securities and reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported in the condensed consolidated statements of comprehensive income (loss).

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed below, the Company believes that the impact of recently issued standards are either not applicable to the Company or will not have a material impact on its consolidated financial statements upon adoption.

The following table provides a brief description of recently issued accounting standards:

Standard

Description

Effective Date

Effect on the Financial Statements or Other Significant Matters

ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures

ASU 2023-07 updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.

Effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024.

The Company is currently evaluating the impact of adopting this standard on its consolidated financial statements and disclosures.

ASU 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures

The amendments in this ASU address investor requests for more transparency about income tax information through improvements to tax disclosures primarily related to the rate reconciliation and income taxes paid information. The ASU also includes certain other amendments to improve the effectiveness of income tax disclosures.

Effective for the Company for annual periods beginning after December 15, 2024, with early adoption permitted.

The Company is currently evaluating the impact of adopting this standard on its consolidated financial statements and disclosures.

Segment Information

Operating segments are components of an enterprise for which separate financial information is available and are evaluated regularly by the Company’s chief operating decision-maker in deciding how to allocate resources and assess performance. The Company manages its business as one operating segment.

3. Business Combination

In connection with, and as contemplated by, the Merger Agreement, on November 1, 2022, in accordance with the terms of the Separation and Distribution Agreement, dated as of March 23, 2022, by and among APAC, Ligand and Legacy OmniAb (the “Separation Agreement”), Ligand transferred the Legacy OmniAb business to Legacy OmniAb and made a contribution to the capital of Legacy OmniAb of $1.8 million, after deducting certain transaction and other expenses reimbursable by Legacy OmniAb (the “Separation”). Following the Separation, Ligand distributed on a pro rata basis to its stockholders all of the shares of common stock, par value $0.001 per share, of Legacy OmniAb (“Legacy OmniAb Common Stock”) held by Ligand, such that each holder of shares of common stock, par value $0.001 per share, of Ligand (“Ligand Common Stock”) was entitled to receive one share of Legacy OmniAb Common Stock for each share of Ligand Common Stock held by such holder as of the record date for the distribution, October 26, 2022 (the “Distribution”). Following the Separation and Distribution, on November 1, 2022, Merger Sub merged with and into Legacy OmniAb, with Legacy OmniAb surviving as a direct, wholly owned subsidiary of OmniAb.

At the Closing Date, each outstanding share of Legacy OmniAb Common Stock was cancelled in exchange for 4.90007 shares of common stock of OmniAb, par value $0.0001 per share (“OmniAb Common Stock”) and 0.75842 shares of OmniAb Common Stock subject to certain price-based earnout triggers (the “Earnout Shares”). Holders of shares of Legacy OmniAb Common Stock received an aggregate 82,611,789 shares of the OmniAb Common Stock, excluding Earnout Shares, as consideration in the Business Combination.

In addition, all outstanding Legacy OmniAb equity awards were converted into OmniAb equity awards to purchase, in the case of options, or receive, in the case of restricted stock units and performance-vesting restricted stock units, shares of OmniAb Common Stock, in each case, equal to the number of shares underlying such Legacy OmniAb equity awards multiplied by 4.90007. Each holder of an outstanding Legacy OmniAb equity award also received Earnout Shares equal to the number of shares of Legacy OmniAb Common Stock underlying such equity award multiplied by 0.75842.

Holders of shares of Legacy OmniAb Common Stock and holders of Legacy OmniAb equity awards received an aggregate 14,999,243 Earnout Shares as consideration in the Business Combination. Fifty percent of the Earnout Shares will vest on the date on which the volume-weighted average price (“VWAP”) equals or exceeds $12.50 on any 20 trading days in any 30 consecutive trading-day period, and all remaining Earnout Shares will vest on the date on which the VWAP equals or exceeds $15.00 on any 20 trading days in any 30 consecutive trading-day period, in each case provided such vesting occurs during the five year period following the Closing Date (the “Earnout Period”); provided, that in the event of a Change of Control (as defined in the Merger Agreement) during the Earnout Period pursuant to which OmniAb or any of its stockholders have the right to receive, directly or indirectly, cash, securities or other property attributing a value of at least $12.50 (with respect to 50% of the Earnout Shares) or $15.00 (with respect to all Earnout Shares) per share of OmniAb Common Stock, and such Change of Control has been approved by a majority of the independent directors of the OmniAb board of directors, then such Earnout Shares shall be deemed to have vested immediately prior to such Change of Control. The Earnout Shares are accounted for as equity-classified equity instruments and recorded in additional paid-in capital as part of the Business Combination.

Pursuant to the Sponsor Insider Letter Agreement executed concurrently with the Merger Agreement, by and among APAC, Avista Acquisition LP II (the “Sponsor”), Legacy OmniAb and certain insiders of APAC, 1,293,299 shares of OmniAb Common Stock held by the Sponsor became subject to the same price-based vesting conditions as the Earnout Shares (the “Sponsor Earnout Shares”). The Sponsor Earnout Shares are accounted for as equity-classified equity instruments and recorded in additional paid-in capital as part of the Business Combination.

On the Closing Date, the Company completed the issuance and sale of 1,500,000 shares of the OmniAb Common Stock and 1,666,667 Forward Purchase Warrants to the Sponsor for an aggregate purchase price of $15.0 million (the “Forward Purchase”), pursuant to the amended and restated forward purchase agreement (the “A&R FPA”). Additionally, and also pursuant to the A&R FPA, on the Closing Date, the Company completed the sale of 8,672,934 shares of the OmniAb Common Stock and 1,445,489 Backstop Warrants to the Sponsor for a purchase price of $10.00 per share and aggregate purchase price of $86.7 million in order to backstop shareholder redemptions which would have otherwise resulted in the cash proceeds available to OmniAb following the Business Combination from OmniAb’s trust account to be less than $100,000,000. Refer to Note 9 – Stockholders' Equity, for additional information on the accounting for the Forward Purchase Warrants and Backstop Warrants.

4. Fair Value Measurement

The Company measures its financial assets and liabilities at fair value, which is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The Company uses the following three-level valuation hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial assets and liabilities:

•Level 1 — Observable inputs such as unadjusted quoted prices in active markets for identical instruments.

•Level 2 — Quoted prices for similar instruments in active markets or inputs that are observable for the asset or liability, either directly or indirectly.

•Level 3 — Significant unobservable inputs based on the Company’s assumptions.

Financial Instruments Measured on a Recurring Basis

The following tables provide a summary of the assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023:


	Fair Value Measurements as of September 30, 2024
(in thousands)	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	17,003	$	—	$	—	$	17,003
Total cash equivalents	$	17,003	$	—	$	—	$	17,003

Short-term investments:
Government and agency securities	$	29,998	$	1,508	$	—	$	31,506
Asset-backed securities	—		639		—		639
Total short-term investments	$	29,998	$	2,147	$	—	$	32,145

Liabilities:
Current contingent liabilities	$	—	$	—	$	510	$	510
Long-term contingent liabilities	—		—		1,111		1,111
Total contingent liabilities	$	—	$	—	$	1,621	$	1,621


	Fair Value Measurements as of December 31, 2023
(in thousands)	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	12,289	$	—	$	—	$	12,289
Total cash equivalents	$	12,289	$	—	$	—	$	12,289

Short-term investments:
Government and agency securities	$	63,109	$	4,998	$	—	$	68,107
Asset-backed securities	—		2,518		—		2,518
Total short-term investments	$	63,109	$	7,516	$	—	$	70,625

Liabilities:
Current contingent liabilities	$	—	$	—	$	1,303	$	1,303
Long-term contingent liabilities	—		—		3,203		3,203
Total contingent liabilities	$	—	$	—	$	4,506	$	4,506

The carrying amounts reported in the Company’s condensed consolidated balance sheets for accounts receivable, other assets, accounts payable and other accrued expenses and other current liabilities approximate fair value due to their relatively short periods to maturity.

Available-for-Sale Securities

The Company obtains the fair value of its Level 2 available-for-sale securities from third-party pricing services. The pricing services utilize industry standard valuation models whereby all significant inputs, including benchmark yields, reported trades, broker/dealer quotes, issuer spreads, bids, offers, or other market-related data, are observable. The Company validates the prices provided by the third-party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources. The Company did not adjust or override any fair value measurements provided by these pricing services as of September 30, 2024 or December 31, 2023. The Company has not transferred any investment securities between classification levels.

Contingent Liabilities

Contingent liabilities are measured at fair value each reporting period by using a probability weighted income approach.

A reconciliation of the Level 3 financial instruments as of September 30, 2024 and December 31, 2023 is as follows:


(in thousands)	Icagen(1)		Taurus(2)		xCella(2)		Total
Balance as of January 1, 2023	$	4,747	$	1,600	$	1,764	$	8,111
Payments to CVR holders	(300)		(1,600)		(2,840)		(4,740)
Fair value adjustments to contingent liabilities	(341)		400		1,076		1,135
Balance as of December 31, 2023	4,106		400		—		4,506
Payments to CVR holders	(75)		(400)		—		(475)
Fair value adjustments to contingent liabilities	(2,410)		—		—		(2,410)
Balance as of September 30, 2024	$	1,621	$	—	$	—	$	1,621

_____________

(1)Changes in the fair values of contingent liabilities in connection with the acquisition of Icagen are recognized in “Other operating expense (income), net” in the condensed consolidated statements of operations and in the operating section of the statements of cash flows. Payments to CVR holders are disclosed in the financing section of the statements of cash flows.

(2)Changes in the fair values of contingent liabilities in connection with the acquisitions of Taurus and xCella are recognized in “Intangible assets, net” in the condensed consolidated balance sheets. Payments to CVR holders are disclosed in the investing section of the statement of cash flows.

Contingent liabilities are classified as Level 3 liabilities as their valuation requires substantial judgment and estimation of factors that are not currently observable in the market. These subjective estimates include but are not limited to assumptions involving the achievement probability of certain developmental and commercialization milestones, discount rates, and projected years of payments. If different assumptions were used for the various inputs to the valuation approaches, the estimated fair value could be materially higher or lower than the fair value determined.

Assets Measured on a Non-Recurring Basis

The Company applies fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to goodwill, finite-lived intangible assets, and long-lived assets. During the nine months ended September 30, 2024 , the Company recorded an impairment of its finite-lived intangible assets related to certain legacy assets from Ligand’s acquisition of Ab Initio in July 2019, as further described in Note 7 – Goodwill and Intangible Assets, Net. No fair value impairment was recognized during the year ended December 31, 2023.

5. Short-Term Investments

The Company classified short-term investments as available-for-sale securities, as the sale of such investments may be required prior to maturity to implement management strategies. The following tables summarize short-term investments as of September 30, 2024 and December 31, 2023:


	As of September 30, 2024
			Unrealized
(in thousands)	Amortized Cost		Gains		Losses		Estimated Fair Value
Government and agency securities	$	31,457	$	50	$	(1)	$	31,506
Asset-backed securities	639		—		—		639
Total short-term investments	$	32,096	$	50	$	(1)	$	32,145


	As of December 31, 2023
			Unrealized
(in thousands)	Amortized Cost		Gains		Losses		Estimated Fair Value
Government and agency securities	$	68,054	$	57	$	(4)	$	68,107
Asset-backed securities	2,522		—		(4)		2,518
Total short-term investments	$	70,576	$	57	$	(8)	$	70,625

The Company classified all investments with maturity dates beyond three months at the date of purchase as short-term investments in the condensed consolidated balance sheets based upon its ability and intent to use the investments to satisfy the liquidity needs of current operations. The following table summarizes available-for-sale investments by maturity as of September 30, 2024:


(in thousands)	Amortized Cost		Estimated Fair Value
Due in one year or less	$	32,096	$	32,145
Due after one year	—		—
Total short-term investments	$	32,096	$	32,145

The following tables summarize the Company’s available-for-sale investments’ gross unrealized losses and fair value aggregated by investment category and length of time that individual securities have been in a continuous loss position, as of September 30, 2024 and December 31, 2023:


	As of September 30, 2024
	Less than 12 months					More than 12 months					Total
(in thousands)	Count	Fair Value		Unrealized Losses		Count	Fair Value		Unrealized Losses		Count	Fair Value		Unrealized Losses
Government and agency securities	1	$	1,508	$	(1)	—	$	—	$	—	1	$	1,508	$	(1)
Asset-backed securities	—	—		—		—	—		—		—	—		—
	1	$	1,508	$	(1)	—	$	—	$	—	1	$	1,508	$	(1)


	As of December 31, 2023
	Less than 12 months					More than 12 months					Total
(in thousands)	Count	Fair Value		Unrealized Losses		Count	Fair Value		Unrealized Losses		Count	Fair Value		Unrealized Losses
Government and agency securities	5	$	10,402	$	(4)	—	$	—	$	—	5	$	10,402	$	(4)
Asset-backed securities	3	2,518		(4)		—	—		—		3	2,518		(4)
	8	$	12,920	$	(8)	—	$	—	$	—	8	$	12,920	$	(8)

The Company had certain available-for-sale debt securities in an unrealized loss position without an allowance for credit loss as of September 30, 2024. Unrealized losses on these debt securities have not been recognized into income because (1) the issuers have high credit quality, (2) management does not intend to sell and it is likely that management will not be required to sell these securities prior to their anticipated recovery and (3) the decline in fair value is largely due to market conditions and/or changes in interest rates. The issuers continue to make timely interest payments on the securities, and the fair value is expected to recover as the bonds approach maturity.

6. Balance Sheet Account Details

Property and Equipment, Net

Property and equipment, net, consisted of the following as of September 30, 2024 and December 31, 2023:


(in thousands)	September 30, 2024		December 31, 2023
Leasehold improvements	$	17,746	$	16,077
Lab and office equipment	9,787		9,452
Computer hardware and software	754		754
Construction in progress	—		842
Property and equipment, at cost	28,287		27,125
Less accumulated depreciation	(11,954)		(8,876)
Total property and equipment, net	$	16,333	$	18,249

Depreciation expense, which is included in operating expense, was $1.0 million and $3.1 million during the three and nine months ended September 30, 2024, respectively, and $1.0 million and $3.0 million during the three and nine months ended September 30, 2023, respectively.

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following as of September 30, 2024 and December 31, 2023:


(in thousands)	September 30, 2024		December 31, 2023
Compensation	$	4,638	$	5,247
Due to former parent Ligand	439		1,234
Professional service fees	189		431
Royalties owed to third parties	116		139
Other	64		17
Total accrued expenses and other current liabilities	$	5,446	$	7,068

7. Goodwill and Intangible Assets, Net

Goodwill and intangible assets, net consisted of the following as of September 30, 2024 and December 31, 2023:


(in thousands)	September 30, 2024		December 31, 2023
Goodwill	$	83,979	$	83,979
Definite-lived intangible assets
Completed technology	233,158		233,158
Less: Accumulated amortization	(94,784)		(84,328)
Customer relationships	11,100		11,100
Less: Accumulated amortization	(5,355)		(4,463)
Intangible assets, net	$	144,119	$	155,467
Total goodwill and other identifiable intangible assets, net	$	228,098	$	239,446

Goodwill

There were no changes in the carrying amount of goodwill during the three and nine months ended September 30, 2024 and 2023.

Intangible Assets

Amortization of finite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of up to 20 years and is reflected within amortization of intangibles expense on the condensed consolidated statements of operations. Amortization expense of $3.4 million and $11.3 million was recognized during the three and nine months ended September 30, 2024, respectively. Amortization expense was $3.4 million and $10.1 million during the three and nine months ended September 30, 2023, respectively.

During the nine months ended September 30, 2024, the Company determined that certain of its finite-lived intangible assets related to the acquisition of Ab Initio in July 2019 were fully impaired, and recorded a $1.2 million write-off of the net carrying value, which is recorded as “Amortization of intangibles” in the condensed consolidated statements of operations.

The remaining weighted-average useful life of definite lived intangible assets is 11.2 years. At September 30, 2024, future amortization expense on intangible assets is estimated to be as follows (in thousands):


Maturity Dates	Amount
Remaining three months ended December 31, 2024	$	3,393
2025	13,452
2026	13,412
2027	13,412
2028	13,412
Thereafter	87,038
Total future amortization expense	$	144,119

8. Commitments and Contingencies

Lease Commitments

The Company’s corporate headquarters are located in Emeryville, California and its research facilities are located in Emeryville and Dixon, California, Durham, North Carolina and Tucson, Arizona. It leases approximately 70,000 square feet of space under leases expiring from 2026 to 2032.

The below tables provide supplemental cash flow and other information related to operating leases (in thousands, except for lease term and discount rate):


	Nine Months Ended September 30,
	2024		2023
Cash paid for amounts included in the measurement of lease liabilities:	$	2,563	$	2,442
Right-of-use assets obtained in exchange for lease obligations:	$	39	$	328


	As of September 30,
	2024		2023
Weighted average remaining lease term (in years)	7.1		8.0
Weighted average discount rate	4.3	%	4.3	%

In addition to base rent, certain of the Company’s operating leases require variable payments. These variable lease costs include amounts relating to common area maintenance and are expensed when the obligation for those payments is incurred and are recognized as operating expenses in the condensed consolidated statements of operations. The following table summarizes the components of operating lease expense for the three and nine months ended September 30, 2024 and 2023:


	Three Months Ended September 30,		Nine Months Ended September 30,
(in thousands)	2024	2023	2024	2023
Operating lease cost	799	802	2,393	2,378
Variable lease cost	519	364	1,337	1,070
Total lease costs	1,318	1,166	3,730	3,448

Future minimum lease commitments are as follows as of September 30, 2024 (in thousands):


Maturity Dates	Operating Leases
Remaining three months ended December 31, 2024	$	930
2025	3,782
2026	3,879
2027	3,980
2028	4,107
Thereafter	11,299
Total lease payments	27,977
Less imputed interest	(4,138)
Present value of lease liabilities	$	23,839

Legal Proceedings

From time to time, the Company has been and may be involved in various legal proceedings arising in its ordinary course of business. In the opinion of management, resolution of any pending claims (either individually or in the aggregate) is not expected to have a material adverse impact on the condensed consolidated financial statements, cash flows or financial position and it is not possible to provide an estimated amount of any such loss. However, the outcome of disputes is inherently uncertain. Therefore, although management considers the likelihood of such an outcome to be remote, an unfavorable resolution of one or more matters could materially affect future results of operations or cash flows, or both, in a particular period.

9. Stockholders' Equity

Authorized and Outstanding Capital Stock

The total number of shares of the Company’s authorized capital stock is 1,100,000,000. The total amount of authorized capital stock consists of 1,000,000,000 shares of common stock and 100,000,000 shares of preferred stock. As of September 30, 2024, no shares of preferred stock are issued or outstanding.

Common Stock

Holders of OmniAb Common Stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. Subject to preferences that may be applicable to any then outstanding preferred stock, holders of OmniAb Common Stock are entitled to receive ratably those dividends, if any, as may be declared by the Company’s board of directors out of legally available funds. In the event of liquidation, dissolution or winding up, the holders of OmniAb Common Stock will be entitled to share ratably in the assets legally available for distribution to stockholders after the payment of or provision for all of the Company's debts and other liabilities, subject to the prior rights of any preferred stock then outstanding. Holders of OmniAb Common Stock have no preemptive or conversion rights or other subscription rights and there are no redemption or sinking fund provisions applicable to the OmniAb Common Stock. All outstanding shares of OmniAb Common Stock are duly authorized, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of OmniAb Common Stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that the Company may designate and issue in the future.

Preferred Stock

Under the terms of the Company’s certificate of incorporation, its board of directors has the authority, without further action by the Company's stockholders, to issue up to 100,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the dividend, voting and other rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding.

The Company’s board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of OmniAb Common Stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deterring or preventing a change in the Company’s control and may adversely affect the market price of OmniAb Common Stock and the voting and other rights of the holders of OmniAb Common Stock. The Company has no current plans to issue any shares of preferred stock.

Earnout Shares

As of September 30, 2024, OmniAb Earnout Shares of 14,999,243 and Sponsor Earnout Shares of 1,293,299 are issued and outstanding. Earnout Shares vest based upon the achievement of certain volume-weighted average trading prices (“VWAP”) for shares of the Company for any 20 trading days over a consecutive 30 trading-day period during the five-year period following the Closing Date, with (i) 50% of such Earnout Shares vesting upon achievement of a VWAP of $12.50 per share of OmniAb Common Stock or upon the occurrence of a change of control transaction that will result in the holders of OmniAb Common Stock receiving a price per share in excess of $12.50, and (ii) the remaining 50% of the Earnout Shares vesting upon achievement of a VWAP of $15.00 per share of OmniAb Common Stock or upon the occurrence of a change of control transaction that will result in the holders of OmniAb Common Stock receiving a price per share in excess of $15.00. The Earnout Shares are not transferable until the vesting condition for the applicable tranche of Earnout Shares has been achieved. Prior to vesting, holders of Earnout Shares are entitled to exercise the voting rights carried by such shares and receive any dividends or other distributions in respect of such shares.

The Earnout Shares will be automatically forfeited for no consideration if the vesting condition for the applicable tranche of Earnout Shares has not been satisfied on or before November 1, 2027.

Warrants

As part of APAC’s initial public offering, 7,666,667 Public Warrants were sold. The Public Warrants entitle the holder thereof to purchase one share of common stock at a price of $11.50 per share, subject to adjustments. The Public Warrants are only exercisable for a whole number of shares of common stock. No fractional shares are to be issued upon exercise of the warrants. The Public Warrants will expire on November 1, 2027 at 5:00 p.m., New York City time, or earlier upon redemption or liquidation. The Public Warrants are listed on the Nasdaq Capital Market under the symbol “OABIW”.

Additionally, the Company can redeem the outstanding Public Warrants:

•in whole and not in part;

•at a price of $0.01 per warrant;

•upon not less than 30 days’ prior written notice of redemption to each warrant holder; and

•if, and only if, the closing price of the ordinary shares equals or exceeds $18.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders provided there was an effective registration statement covering the shares of common stock issuable upon exercise of the warrants.

If the Company calls the Public Warrants for redemption as previously described, the Company has the option to require all holders that wish to exercise the Public Warrants to do so on a cashless basis.

Simultaneously with APAC’s initial public offering, APAC consummated a private placement of 8,233,333 Private Placement Warrants with APAC’s sponsor. Each Private Placement Warrant is exercisable for one share of common stock at a price of $11.50 per share, subject to adjustment. The Private Placement Warrants have terms and provisions that are identical to those of the Public Warrants except that the Private Placement Warrants were not transferable, assignable or salable until 30 days after the completion of the Business Combination. The Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the Public Warrants.

Additionally, on the Closing Date, the Company issued 1,666,667 Forward Purchase Warrants and 1,445,489 Backstop Warrants pursuant to the A&R FPA. The Forward Purchase Warrants and Backstop Warrants have the same terms as the Private Placement Warrants.

The Company concluded the Public, Private Placement, Forward Purchase and Backstop Warrants meet the criteria to be classified as equity. Upon consummation of the Business Combination, the Public, Private Placement, Forward Purchase and Backstop Warrants were recorded in additional paid-in capital.

Equity Compensation Plans

2022 Incentive Award Plan

The Company’s board of directors and stockholders adopted the 2022 Incentive Award Plan, or the 2022 Plan, which became effective upon the Closing of the Business Combination. Under the 2022 Plan, the Company may grant cash and equity incentive awards to eligible employees, directors and consultants.

As of September 30, 2024, the aggregate number of shares of our common stock that may be issued under the 2022 Plan is 29,629,470 shares. In addition, the number of shares of our common stock available for issuance under the 2022 Plan will be annually increased on January 1 of each calendar year beginning in 2023 and ending in 2032 by an amount equal to the lesser of (i) a number equal to 5% of the fully-diluted shares on the final day of the immediately preceding calendar year or (ii) such smaller number of shares as is determined by the Company's board of directors.

The 2022 Plan provides for the grant of stock options, including incentive stock options and nonqualified stock options, stock appreciation rights, restricted stock, dividend equivalents, RSUs and other stock or cash-based awards.

OmniAb Prior Plans

In connection with the Business Combination, Legacy OmniAb adopted the OmniAb, Inc. 2022 Ligand Service Provider Assumed Award Plan and the OmniAb, Inc. 2022 OmniAb Service Provider Assumed Award Plan, collectively referred to as the OmniAb Prior Plans, which govern the OmniAb equity awards issued upon adjustment of outstanding Ligand equity awards in connection with the Distribution. All awards under the OmniAb Prior Plans that were outstanding as of the closing of the Business Combination continued to be governed by the terms, conditions and procedures set forth in the OmniAb Prior Plans and any applicable award agreements, as those terms may be equitably adjusted in connection with the Business Combination. The Company assumed the OmniAb Prior Plans in connection with the closing of the Business Combination, and each of the awards thereunder.

At the Market Offering

In December 2023, the Company entered into an Open Market Sale AgreementSM (the “Sales Agreement”), with Jefferies LLC (the “Sales Agent”) under which it may, from time to time, sell shares of its common stock having an aggregate offering price of up to $100.0 million in “at the market” (“ATM”) offerings through the Sales Agent. Sales of the shares of common stock, if any, will be made at prevailing market prices at the time of sale, or as otherwise agreed with the Sales Agent. The Sales Agent will receive a commission from the Company of up to 3.0% of the gross proceeds of any shares of common stock sold under the Sales Agreement. Sales of its common stock made pursuant to the Sales Agreement are made under its shelf registration statement on Form S‐3 which was filed on December 8, 2023 and declared effective by the SEC on December 18, 2023. The Company is not obligated to sell, and the Sales Agent is not obligated to buy or sell, any shares of common stock under the Sales Agreement. During the three and nine months ended September 30, 2024, 2,029,978 shares of common stock in the ATM offering were issued for net proceeds of $8.5 million, after deducting commissions. Subsequent to September 30, 2024, the Company issued 741,214 shares of common stock under the ATM program for net proceeds of $2.9 million, after deducting commissions.

10. Share-Based Compensation

Share-Based Compensation Expense

The Company recognized share-based compensation expense by function as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
General and administrative	$	2,733	$	3,113	$	8,266	$	9,106
Research and development	2,572		3,197		8,117		9,788
Total share-based compensation expense	$	5,305	$	6,310	$	16,383	$	18,894

The Company recognized share-based compensation expense by award type as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Stock options	$	3,659	$	3,866	$	11,162	$	11,461
Restricted stock units	1,429		2,001		4,421		5,882
Performance restricted stock units	154		154		460		458
Employee share purchase plan	63		289		340		1,093
Total share-based compensation expense	$	5,305	$	6,310	$	16,383	$	18,894

Stock Options

Stock options granted under the 2022 Plan typically vest 1/8 on the six-month anniversary of the date of grant, and 1/48 each month thereafter for 42 months. All option awards generally expire 10 years from the date of grant.

The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock options granted. The model assumptions include expected volatility, expected term, dividend yield, and the risk-free interest rate.

•Expected volatility: Due to the Company’s limited trading history for its common stock, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.

•Expected term: The expected term represents the period of time that options are expected to be outstanding. Because the Company has limited historical exercise behavior, it determines the expected life assumption using the simplified method which is an average of the contractual term of the option and its vesting period.

•Dividend yield: The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero.

•Risk-free interest rate: The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.

The fair value of each option issued to employees was estimated on the grant date using the Black-Scholes option pricing model with the following weighted-average assumptions:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Risk-free interest rate	4.1	%	4.3	%	4.3	%	3.6	%
Expected volatility	55.7	%	50.7	%	54.4	%	50.1	%
Expected term (years)	6.0		6.1		6.0		6.1
Dividend yield	—	%	—	%	—	%	—	%

The following table summarizes stock option activity awarded to OmniAb employees and directors under the Company’s equity award plans:


	Shares	Weighted-Average Exercise Price per Share		Weighted-Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value (in thousands)(1)
Outstanding at January 1, 2024	14,795,859	$	6.50
Granted	3,170,425	$	5.50
Exercised	(472,035)	$	3.65
Cancelled/Expired	(475,134)	$	6.12
Outstanding at September 30, 2024	17,019,115	$	6.40	8.0	$	4,205
Exercisable at September 30, 2024	7,483,410	$	7.84	7.4	$	1,568

_____________

(1)The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for in the money options at September 30, 2024.

As of September 30, 2024, unrecognized share-based compensation expense related to OmniAb options was $24.6 million, which is expected to be recognized over a remaining weighted-average period of approximately 1.25 years. As of September 30, 2024, unrecognized share-based compensation expense related to Ligand options was $0.7 million, which is expected to be recognized over a remaining weighted-average period of approximately 0.34 years.

The aggregate intrinsic value of OmniAb options exercised by OmniAb employees during the nine months ended September 30, 2024 was $0.5 million. Cash received from OmniAb options exercised by OmniAb employees during the nine months ended September 30, 2024 was $1.5 million.

There were no OmniAb options exercised by Ligand employees during the nine months ended September 30, 2024.

Restricted Stock Units

RSUs generally represent the right to receive a certain number of shares of common stock subject to certain vesting conditions and other restrictions. RSUs generally vest over three years. The fair value of RSUs is determined by the closing market price on the grant date.

The following table summarizes RSU activity during the nine months ended September 30, 2024 under the Company’s equity awards plans:


	Shares	Weighted-Average Grant Date Fair Value
Unvested balance at January 1, 2024	1,878,381	$	5.61
Granted	906,064	$	5.41
Vested	(632,505)	$	7.43
Forfeited	(81,438)	$	4.26
Unvested balance at September 30, 2024	2,070,502	$	5.01

As of September 30, 2024, unrecognized stock-based compensation expense related to OmniAb RSUs was $7.0 million, which is expected to be recognized over a remaining weighted-average period of approximately 1.29 years. As of September 30, 2024, unrecognized stock-based compensation expense related to Ligand RSUs was negligible.

The aggregate intrinsic value of OmniAb RSUs vested for OmniAb employees during the nine months ended September 30, 2024 was $3.4 million. The aggregate intrinsic value of OmniAb RSUs vested for Ligand employees during the nine months ended September 30, 2024 was $0.7 million.

Performance Restricted Stock Units

PRSUs generally represent the right to receive a certain number of shares of common stock based on the achievement of the Company’s corporate performance or market goals and continued employment during the vesting period.

The Company’s PRSUs contain a market condition dependent upon the Company’s relative and absolute total stockholder return over a three-year period, with a payout range of 0% to 200% of the target shares granted. Share-based compensation expense for these PRSUs is measured using the Monte-Carlo valuation model and is not adjusted for the achievement, or lack thereof, of the market conditions.

The following table summarizes the PRSU activity during the nine months ended September 30, 2024, under the Company’s equity awards plans:


	Shares	Weighted-Average Grant Date Fair Value
Unvested balance at January 1, 2024	94,749	$	16.11
Granted	—	$	—
Vested	—	$	—
Forfeited	—	$	—
Unvested balance at September 30, 2024	94,749	$	16.11

As of September 30, 2024, unrecognized share-based compensation expense related to OmniAb PRSUs was $0.2 million, which is expected to be recognized over a remaining weighted-average period of approximately 0.25 years.

Employee Stock Purchase Plan

Under the Company’s 2022 Employee Stock Purchase Plan (the “ESPP”), eligible employees are entitled to purchase shares of common stock at a discount with accumulated payroll deductions. The ESPP provides for a series of overlapping 24-month offering periods comprising four six-month purchase periods. The initial offering period under the 2022 ESPP is longer than 24 months, commencing November 1, 2022 and ending on November 29, 2024. The purchase price for shares of common stock purchased under the ESPP is equal to 85% of the lesser of the fair market value of the Company’s common stock on (i) the first trading day of the applicable offering period or (ii) the last trading day of each six month purchase period in the applicable offering period.

As of September 30, 2024, the aggregate number of shares of our common stock that may be issued pursuant to rights granted under the ESPP equals 3,053,749 shares of our common stock. In addition, on the first day of each calendar year beginning on January 1, 2023 and ending on (and including) January 1, 2032, the number of shares available for issuance under the ESPP will be increased by a number of shares equal to the lesser of (i) 1% of the fully diluted shares outstanding on the final day of the immediately preceding calendar year, and (ii) such smaller number of shares as determined by our board of directors.

As of September 30, 2024, there was $0.1 million of unrecognized share-based compensation expense associated with the ESPP, which is expected to be recognized over a remaining weighted-average period of 0.51 years.

During the nine months ended September 30, 2024, there were 340,829 shares issued pursuant to the ESPP.

11. Income Taxes

The Company’s effective tax rate may vary from the U.S. federal statutory tax rate due to the change in the mix of earnings in various state jurisdictions with different statutory rates, benefits related to tax credits, and the tax impact of non-deductible expenses, stock award activities and other permanent differences between income before income taxes and taxable income. The Company’s effective tax rate for both the three and nine months ended September 30, 2024 was 14.2% and 12.9%, respectively. The variance from the U.S. federal statutory tax rate of 21.0% for the three and nine months ended September 30, 2024 was primarily due to the benefit related to tax credits, the tax impact of stock award activities, and the valuation allowance established on federal and state attributes. The Company’s effective tax rate for the three and nine months ended September 30, 2023 was 17.4% and 17.5%, respectively. The variance from the U.S. federal statutory tax rate of 21.0% for the three and nine months ended September 30, 2023 was primarily due to the benefit related to tax credits, the tax impact of stock award activities, and the valuation allowance established on state attributes.

The Company considered the realizability of the deferred tax assets and recorded a valuation allowance as necessary for the amount of deferred tax assets which are not more likely than not to be realized as of September 30, 2024.

12. Net Loss Per Share

Loss Per Share

Basic loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares and dilutive common shares outstanding during the period. As described in Note 2 – Summary of Significant Accounting Policies, Earnout Shares issued in connection with the Business Combination, as further described in Note 3 – Business Combination, are subject to vesting based on the VWAP of common shares during the earnout period. The Earnout Shares are excluded from the calculation of basic and diluted weighted-average number of common shares outstanding until vested.

The following table outlines the basic and diluted net loss per share for the three and nine months ended September 30, 2024 and 2023:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands, except per share data)	2024		2023		2024		2023
Net loss	$	(16,373)	$	(15,738)	$	(48,965)	$	(36,566)
Weighted-average shares outstanding, basic and diluted	102,393		99,905		101,538		99,521
Net loss per share, basic and diluted	$	(0.16)	$	(0.16)	$	(0.48)	$	(0.37)

The following table outlines dilutive common share equivalents outstanding, which are excluded in the above diluted net loss per share calculation, as the effect of their inclusion would be anti-dilutive, or the share equivalents were contingently issuable as of each period presented:


	September 30,
	2024	2023
Options to purchase common stock issued and outstanding(1)	22,132,077	21,076,042
Earnout shares	16,292,542	16,292,542
Avista private placement warrants	8,233,333	8,233,333
Avista public warrants	7,666,667	7,666,667
Restricted stock units issued and outstanding(1)	2,165,251	2,338,820
Forward purchase warrants	1,666,667	1,666,667
Backstop warrants	1,445,489	1,445,489
Shares expected to be purchased under employee stock purchase plan	687,882	1,433,978
Total anti-dilutive shares	60,289,908	60,153,538

_____________

(1)Outstanding stock options and restricted stock units include awards outstanding to employees of Ligand.

Item 2. Management's Discussion and Analysis of Financial

Condition and Results of Operations

The following discussion and analysis and the unaudited interim financial statements included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2023 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in the Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”).

Forward-Looking Statements

This Quarterly Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, our expected cash runway, our business strategy, our expectations regarding the application of, and the rate and degree of market acceptance of our OmniAb® technology platform and other technologies, our expectations regarding the addressable markets for our technologies, including the growth rate of the markets in which we operate, the potential for and timing of receipt of milestones and royalties under our license agreements with partners, our research and development plans, the potential for our partnered or internal programs to progress in their development, the anticipated timing of the initiation and completion of preclinical studies and clinical trials by our partners or us, the timing and likelihood of regulatory filings and product approvals by our partners or us, the potential for and timing and geographic markets of any commercial product launches by our partners and potential for commercial success, our ability to enter into any new, or maintain existing, strategic partnerships or collaborative relationships, our ability to obtain and maintain intellectual property protection for our platform, products and technologies, the timing and likelihood of success, plans and objectives of management for future operations, and future results of anticipated business development and product development efforts, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of risks, uncertainties and assumptions, including, without limitation, the risk factors described in Part II, Item 1A, “Risk Factors” of this Quarterly Report. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Overview

OmniAb licenses cutting edge discovery research technology to the pharmaceutical and biotech industries and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is what we call Biological Intelligence™, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. We primarily derive revenue from license fees for technology access, milestones from partnered programs and service revenue from research programs.

We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, are used to identify fully-human antibodies with exceptional performance and developability characteristics. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions.

As of September 30, 2024, we had 86 active partners with 352 active programs using the OmniAb technology platform, including 29 OmniAb-derived antibodies in clinical development by our partners, one under regulatory review, and three approved products of our partners.

Our proprietary technologies are joined with and leverage a suite of in silico, artificial intelligence and machine learning tools for therapeutic discovery and optimization that are woven throughout our various technologies and capabilities. Additionally, an established core competency focused on ion channels and transporters further differentiates OmniAb’s technology and creates opportunities in many important and emerging target classes. OmniAb technologies are designed to be leveraged for the discovery of a variety of next-generation antibody-based therapeutic modalities, including bi- and multi-specific biologics, antibody-drug conjugates, CAR-T therapies, targeted radiotherapeutics, and many others.

The OmniAb suite of technologies spans from Biological Intelligence-powered repertoire generation to cutting-edge antibody discovery and optimization offering an increasingly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry.

We partner with pharmaceutical and biotechnology companies and leading academic institutions that vary in size, clinical stage, geography and therapeutic focus. Our partners gain access to wide repertoires of antibodies and state-of-the-art screening technologies designed to enable efficient discovery of next-generation novel therapeutics and deliver high-quality therapeutic antibody candidates for a wide range of diseases. Our partners can select a biological target to treat a disease and define the antibody properties needed for therapeutic development or use certain of our technologies directly in their own laboratories.

Our license agreements with pharmaceutical and biotechnology partners generally include: (i) upfront or, in some instances, annual payments for technology access and payments for performance of research services; (ii) downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones; and (iii) royalties on net sales of our partners’ products, if any. License agreements with academic institutions are typically structured with revenue sharing. We succeed when our partners are successful, and our agreements are structured to align economic and scientific interests. Our license agreements typically include reporting requirements, which provide us updates from our partners on the status of their programs. In addition, we track our active partnered programs by reviewing our partners’ public announcements and maintaining close communications with our partners to the extent possible. In some instances, a partner may not publicly announce milestones, in which case, we would be generally dependent on our partner to track, report and disclose to us milestones at the time of achievement. Our license agreements typically grant a perpetual license to our technology and are typically terminable by our partners without penalty with specified notice. However, all milestone payments and royalties survive termination and continue with respect to any OmniAb-derived antibodies. The royalty term is generally the longer of 10 years from the first commercial sale or through the last expiration in any jurisdiction of the patents covering such OmniAb-derived antibody. Importantly, our royalty term is typically linked to the composition-of-matter patents that our partners file related to the antibody discovered using our technology, which both lengthens and diversifies the royalty streams we receive. Our typical royalty rates for antibody discovery contracts are currently in the low- to mid-single digits and can vary depending on other economic terms in the agreement. Although our license agreements with pharmaceutical and biotechnology partners typically include technology access fees, milestone payments and royalties, each agreement is negotiated separately and as a result, the financial terms and contractual provisions vary from agreement to agreement. By providing a full suite of antibody discovery technologies with streamlined economics, we believe we offer an attractive option to industry stakeholders.

We believe the long-term value of our business will be driven by royalties given that such payments are based on global sales of potential future partner programs, which generally provide for larger and recurring payments as compared to technology access, research and milestone payments. We believe our revenue will be materially driven by milestones in the shorter term, and by royalties in the longer term, from our partnered programs. However, there is significant uncertainty in timing and likelihood of reaching marketing authorization in drug discovery and development, and we cannot be certain when, if at all, royalty payments will be a material portion of our revenue. Furthermore, we do not control the progression, clinical development, regulatory strategy or eventual commercialization of programs discovered using our platform, and as a result, we are dependent on our partners’ efforts and decisions with respect to such programs.

Key Business Metrics

We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. We believe that the following metrics are important to understanding our current business. These metrics are highly dependent on information provided by our partners and may change or may be substituted for additional or different metrics as our business continues to grow.


Metric	Active Partners	Active Programs	Active Clinical Programs and Approved Products	Approved Products
December 31, 2023	77	325	32	3
Additions	10	39	3	—
Terminations	(1)	(12)	(2)	—
September 30, 2024	86	352	33	3

Active partners represents the number of partners that have rights to an active program or have executed a license agreement in advance of initiating an active program. A partner is removed from the metric when the partner informs us they are terminating their license or they are no longer in business. We view this metric as an indication of the competitiveness of our platform and our current level of market penetration. The metric also relates to our opportunities to secure additional active programs.

Active programs represents a program for which research work has commenced or where an antigen is introduced into our animals and remains so as long as the program is actively being developed or commercialized. This number includes active clinical programs and approved products separately disclosed in the table above. We view this metric as an indication of the usage of our technology and the potential for mid- and long-term milestone and royalty payments.

Active clinical programs and approved products represents the number of unique programs for which an Investigational New Drug Application or equivalent under other regulatory regimes has been filed based on an OmniAb-derived antibody and which are in clinical development by our partners. We continue to count programs as active as long as they are actively being developed, under regulatory review or commercialized. Where the date of such application is not known to us, we use the official start date from clinical trial registries for the purpose of calculating this metric. This number includes approved products separately disclosed in the table above. We view this metric as an indication of our near- and mid-term potential revenue from milestone fees and potential royalty payments in the long term.

Approved products represents an OmniAb-derived antibody for which our partner has received marketing approval. We view this metric as an indication of our near- and mid-term potential revenue from royalty payments.

Results of Operations

Comparison of the Three and Nine Months Ended September 30, 2024 and 2023

Revenue


	Three Months Ended September 30,
(Dollars in thousands)	2024		2023		Change		% Change
License and milestone revenue	$	1,375	$	2,010	$	(635)	(32)	%
Service revenue	2,479		3,016		(537)		(18)	%
Royalty revenue	318		451		(133)		(29)	%
Total revenue	$	4,172	$	5,477	$	(1,305)	(24)	%

•License and milestone revenue fluctuates primarily due to the timing of upfront license payments and milestone recognition related to our partners’ programs in clinical development. The decline in license and milestone revenue was primarily driven by more milestone payments recognized in the prior year period.

•Service revenue declined primarily as a result of the discontinuation of certain ion channel research programs.

•Royalty revenue declined primarily due to lower net sales from partners’ product sales.


	Nine Months Ended September 30,
(Dollars in thousands)	2024		2023		Change		% Change
License and milestone revenue	$	5,216	$	18,986	$	(13,770)	(73)	%
Service revenue	9,416		9,425		(9)		0	%
Royalty revenue	955		931		24		3	%
Total revenue	$	15,587	$	29,342	$	(13,755)	(47)	%

•The decline in license and milestone revenue was primarily driven by (1) the recognition in the prior year period of a $10 million milestone related to the first commercial sale of TECVAYLI® (teclistamab) in the European Union, (2) the recognition in the prior year period of $2.5 million of milestones related to the start of pivotal studies in two additional indications for batoclimab, and (3) several smaller milestones and license payments, each of which was immaterial.

Operating Expenses


	Three Months Ended September 30,
(Dollars in thousands)	2024		2023		Change		% Change
Research and development	$	13,318	$	13,867	$	(549)	(4)	%
General and administrative	7,079		8,511		(1,432)		(17)	%
Amortization of intangibles	3,393		3,398		(5)		0	%
Other operating expense (income), net	146		16		130		813	%
Total operating expenses	$	23,936	$	25,792	$	(1,856)	(7)	%

•Research and development expenses declined primarily due to lower share-based compensation expenses.

•General and administrative expenses decreased primarily due to lower legal and share-based compensation expense.

•Other operating expense, net, increased primarily due to an increase in contingent liabilities associated with changes in ion channel programs.


	Nine Months Ended September 30,
(Dollars in thousands)	2024		2023		Change		% Change
Research and development	$	41,804	$	41,759	$	45	0	%
General and administrative	23,381		25,444		(2,063)		(8)	%
Amortization of intangibles	11,348		10,147		1,201		12	%
Other operating expense (income), net	(2,324)		205		(2,529)		(1234)	%
Total operating expenses	$	74,209	$	77,555	$	(3,346)	(4)	%

•Research and development expenses increased slightly as a result of increased contract research expenses and facility and other overhead expenses, partially offset by lower share-based compensation expenses.

•General and administrative expenses decreased primarily due to non-recurring consulting and other outside service expenses incurred in 2023 related to our separation from Ligand to become a standalone public company as well as lower legal and share-based compensation expense.

•Amortization of intangibles increased primarily due to a $1.2 million impairment of certain of our finite-lived intangible assets related to legacy acquired assets.

•Other operating income, net increased primarily due to a $2.4 million reduction in contingent liabilities attributed to changes in ion channel programs.

Research and Development Expenses

Research and development expenses consist of (1) personnel related expenses, including salaries, benefits and share-based compensation, (2) external expenses, including third-party costs for goods and services such as lab supplies and contract research, and (3) facility and other overhead expenses, including depreciation and occupancy costs.


	Three Months Ended September 30,
(Dollars in thousands)	2024		2023		Change		% Change
Personnel related expenses	$	6,756	$	7,244	$	(488)	(7)	%
External expenses	3,850		4,015		(165)		(4)	%
Facility and other overhead expenses	2,712		2,608		104		4	%
Total research and development expenses	$	13,318	$	13,867	$	(549)	(4)	%


	Nine Months Ended September 30,
(Dollars in thousands)	2024		2023		Change		% Change
Personnel related expenses	$	21,469	$	21,881	$	(412)	(2)	%
External expenses	12,388		12,094		294		2	%
Facility and other overhead expenses	7,947		7,784		163		2	%
Total research and development expenses	$	41,804	$	41,759	$	45	0	%

Other Income (Expense), net

Other income (expense), net during the three and nine months ended September 30, 2024 and 2023 primarily related to interest earned on short-term investments. The decline in interest income related to lower short-term investment balances as well as declines in interest rates.

Income Tax Benefit


	Three Months Ended September 30,
(Dollars in thousands)	2024			2023			Change		% Change
Loss before income taxes	$	(19,081)		$	(19,042)		$	(39)	0	%
Income tax benefit	2,708			3,304			(596)		(18)	%
Net loss	$	(16,373)		$	(15,738)		$	(635)	4	%
Effective tax rate	(14.2)		%	(17.4)		%


	Nine Months Ended September 30,
(Dollars in thousands)	2024			2023			Change		% Change
Loss before income taxes	$	(56,188)		$	(44,335)		$	(11,853)	27	%
Income tax benefit	7,223			7,769			(546)		(7)	%
Net loss	$	(48,965)		$	(36,566)		$	(12,399)	34	%
Effective tax rate	(12.9)		%	(17.5)		%

Our effective tax rate is affected by recurring items, such as the U.S. federal and state statutory tax rates and the relative amounts of income we earn in those jurisdictions. The tax rate is also affected by discrete items that may occur in any given year but are not consistent from year to year.

Our effective tax rate for the three and nine months ended September 30, 2024 differed from the federal statutory tax rate of 21.0% due to share-based compensation expense that is not tax deductible and an increase to our valuation allowance recorded against deferred tax assets, partially offset by the tax benefit from research and development tax credits. Our effective tax rate for the three and nine months ended September 30, 2023 differed from the federal statutory tax rate of 21.0% due to share-based compensation expense that is not tax deductible and increases to our valuation allowance recorded against deferred tax assets, partially offset by the tax benefit of research and development tax credits.

Liquidity and Capital Resources

Prior to our spin-off from Ligand Pharmaceuticals Incorporated (“Ligand”) in November 2022, funding from Ligand was our primary source of liquidity. We were capitalized with $95.8 million in net cash in connection with the closing of the business combination pursuant to which OmniAb Operations, Inc., a then wholly-owned subsidiary of Ligand (“OmniAb Operations”), was spun off and merged with Orwell Merger Sub Inc., our then wholly-owned subsidiary, with OmniAb Operations surviving as our wholly-owned subsidiary.

As of September 30, 2024, our cash, cash equivalents and short-term investments were $59.4 million. We believe our cash, cash equivalents and short-term investments are sufficient to support our operations through at least the next 12 months.

If our anticipated cash flows from operations and current cash are insufficient to satisfy our liquidity requirements because of increased expenditures or lower demand for our technology platform, or the realization of other risks, we may be required to raise additional capital through issuances of public or private equity or debt financing or other capital sources. Such additional financing may not be available on terms acceptable to us or at all. In any event, we may consider raising additional capital in the future to expand our business, to pursue strategic investments or acquisitions, to take advantage of favorable market conditions or financing opportunities or for other reasons. Our future capital requirements will depend on many factors, including, but not limited to:

•our ability to achieve revenue growth;

•the costs of expanding our operations, including our business development and marketing efforts;

•our rate of progress in selling access to our platform and marketing activities associated therewith;

•our rate of progress in, and cost of research and development activities associated with, our platform technologies and our internal developed programs to the extent we pursue any such programs;

•the effect of competing technological and market developments;

•the impact of pandemic or epidemic diseases on global social, political and economic conditions;

•our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company;

•the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patents and other intellectual property and proprietary rights; and

•the costs associated with any technologies that we may in-license or acquire.

In December 2023, we entered into an Open Market Sale AgreementSM (the “Sales Agreement”), with Jefferies LLC (the “Sales Agent”) under which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $100.0 million in an “at the market” (“ATM”) offerings program through the Sales Agent. Sales of the shares of common stock, if any, will be made at prevailing market prices at the time of sale, or as otherwise agreed with the Sales Agent. The Sales Agent will receive a commission from us of up to 3.0% of the gross proceeds of any shares of common stock sold under the Sales Agreement. Sales of our common stock made pursuant to the Sales Agreement are made under our shelf registration statement on Form S‐3 which was filed on December 8, 2023 and declared effective by the SEC on December 18, 2023. We are not obligated to sell, and the Sales Agent is not obligated to buy or sell, any shares of common stock under the Sales Agreement.

We anticipate that our principal uses of cash in the future will be primarily to fund our operations, working capital needs, capital expenditures and other general corporate purposes.

Additionally, we may receive up to $218.6 million from the exercise of our warrants, assuming the exercise in full of all the warrants for cash, but not from the sale of the shares of our common stock issuable upon such exercise. As of the date of this report, our warrants are “out of the money,” which means that the trading price of the shares of our common stock underlying our warrants is below the $11.50 exercise price of the warrants. For so long as the warrants remain out of the money, we do not expect warrant holders to exercise their warrants. Therefore, any cash proceeds that we may receive in relation to the exercise of such securities will be dependent on the trading price of our common stock.

Cash Flow Summary


	Nine Months Ended September 30,
(Dollars in thousands)	2024		2023		Change
Net cash provided by (used in):
Operating activities	$	(35,792)	$	11,468	$	(47,260)
Investing activities	37,499		(23,106)		60,605
Financing activities	$	9,171	$	(396)	$	9,567

Cash from Operating Activities:

During the nine months ended September 30, 2024, cash used in operating activities of $35.8 million primarily reflected our net loss of $49.0 million, changes in our operating assets and liabilities in the amount of $8.8 million, partially offset by net non-cash charges of $22.0 million which primarily included $16.4 million in share-based compensation and $16.0 million in depreciation and amortization.

During the nine months ended September 30, 2023, cash provided by operating activities of $11.5 million primarily reflected changes in our operating assets and liabilities in the amount of $24.9 million, net non-cash charges of $23.2 million which primarily included $18.9 million in share-based compensation, and $14.6 million in depreciation and amortization, partially offset by our net loss of $36.6 million.

Cash from Investing Activities:

During the nine months ended September 30, 2024, cash provided by investing activities of $37.5 million primarily consisted of $63.5 million of proceeds from the maturity of short-term investments and $1.9 million from the sale of short-term investments, partially offset by $25.7 million of cash used to purchase short-term investments and $1.8 million of cash used to purchase property and equipment.

During the nine months ended September 30, 2023, cash used in investing activities of $23.1 million primarily consisted of $86.9 million of cash used to purchase short-term investments and $3.6 million of payments to contingent liabilities holders, partially offset by $66.3 million of proceeds from the maturity of short-term investments.

Cash from Financing Activities:

During the nine months ended September 30, 2024, cash provided by financing activities was $9.2 million, which primarily consisted of $8.5 million of proceeds from the issuance of common stock under the ATM facility, net of commissions and $2.3 million of proceeds from the issuance of common stock from stock plans, partially offset by $1.0 million of taxes paid related to the net share settlement of equity awards and $0.5 million of transaction costs.

During the nine months ended September 30, 2023, cash used in financing activities was $0.4 million, which primarily consisted of $0.9 million of taxes paid related to the net share settlement of equity awards and $0.5 million of transaction costs, partially offset by $1.0 million of proceeds from the issuance of common stock from stock plans.

Critical Accounting Policies and Estimates

There have been no material changes to our critical accounting policies and estimates during the nine months ended September 30, 2024, as compared to the critical accounting policies and estimates disclosed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the 2023 Annual Report.

Recent Accounting Pronouncements

For the summary of recent accounting pronouncements, see Note 2 – Summary of Significant Accounting Policies to our financial statements included in this Quarterly Report.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

As of September 30, 2024, there were no material changes to our market risks from the discussion provided in Item 7A of our 2023 Annual Report.

Item 4. Controls and Procedures

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2024, the end of the period covered by this Quarterly Report. Based upon such evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Part II – Other Information

Item 1. Legal Proceedings

For information that updates the disclosures set forth under Part I, Item 3, “Legal Proceedings” in our 2023 Annual Report, refer to Note 8 – Commitments and Contingencies to the condensed consolidated financial statements contained in Part I, Item 1, of this report.

From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. However, regardless of outcome, litigation can have an adverse impact on our business because of defense and settlement costs, diversion of management resources and other factors, and there can be no assurances that favorable outcomes will be obtained.

Item 1A. Risk Factors

We do not believe that there have been any material changes to the risk factors disclosed in Part I, Item 1A of our 2023 Annual Report. The risk factors described in our 2023 Annual Report are not the only risks we face. Factors we currently do not know, factors that we currently consider immaterial or factors that are not specific to us, such as general economic conditions, may also materially adversely affect our business or our consolidated operating results, financial condition or cash flows.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Rule 10b5-1 Trading Arrangements

From time to time, our officers (as defined in Rule 16a-1(f) of the Exchange Act) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended September 30, 2024, none of our officers or directors adopted, modified, or terminated any such trading arrangements.

Item 6. Exhibits

Incorporated by Reference

Exhibit

Number

Description of Exhibit

Form

File Number

Date of Filing

Exhibit

Number

Filed

Herewith

2.1+

Agreement and Plan of Merger, dated March 23, 2022, by and among Avista Public Acquisition Corp. II, Orwell Merger Sub Inc., Ligand Pharmaceuticals Incorporated and OmniAb, Inc.

S-4

333-264525

September 27, 2022

2.1

2.2+

Separation and Distribution Agreement, dated March 23, 2022, by and among Avista Public Acquisition Corp. II, Ligand Pharmaceuticals Incorporated and OmniAb, Inc.

S-4

333-264525

September 27, 2022

2.2

3.1

Certificate of Incorporation of the Registrant

10-K

001-40720

March 30, 2023

3.1

3.2

Bylaws of the Registrant

8-K

001-40720

November 7, 2022

3.2

4.1

Warrant Agreement, dated August 9, 2021, between Avista Public Acquisition Corp. II and Continental Stock Transfer & Trust Company, as warrant agent

8-K

001-40720

August 12, 2021

4.1

4.2

Assignment, Assumption and Amendment Agreement, dated November 1, 2022, by and among OmniAb, Inc., Continental Stock Transfer & Trust Company and Computershare Trust Company, N.A.

8-K

001-40720

November 7, 2022

4.2

4.3

Specimen Warrant Certificate

S-1/A

333-257177

July 28, 2021

4.3

4.4

Specimen Common Stock Certificate of OmniAb, Inc.

S-4

333-264525

September 27, 2022

4.5

31.1

Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2

Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1*

Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2*

Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Calculation Linkbase Document

101.DEF

Inline XBRL Taxonomy Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

_____________

+ Certain schedules and annexes have been omitted in accordance with Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or annex will be furnished as a supplement to the SEC upon request.

* This certification is deemed not filed for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Date:	November 12, 2024	By:	/s/ Kurt Gustafson
			Kurt Gustafson
			Executive Vice President, Finance and Chief Financial Officer
			(Principal Financial and Accounting Officer)

Get the next $OABI alert in real time by email

Date	Price Target	Rating	Analyst
11/29/2023	$6.00	Outperform	RBC Capital Mkts
4/21/2023	$8.00	Buy	The Benchmark Company
4/13/2023	$10.00	Buy	Craig Hallum
2/22/2023	$10.00	Outperform	Cowen
2/13/2023	$11.00	Buy	H.C. Wainwright

SEC Form 10-Q filed by OmniAb Inc.

Chat with this insight

Recent Analyst Ratings for $OABI

$OABI SEC Filings

SEC Form 10-Q filed by OmniAb Inc.

OmniAb Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by OmniAb Inc.

$OABI Financials

Live finance-specific insights

$OABI Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$OABI Large Ownership Changes

This live feed shows all institutional transactions in real time.

$OABI Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$OABI Market Insights

Live Market Insights

OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights

OmniAb to Report Third Quarter 2024 Financial Results on November 12

OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights

Foehr Matthew W bought $1,059,840 worth of shares (240,000 units at $4.42), increasing direct ownership by 7% to 3,536,665 units (SEC Form 4)

Foehr Matthew W bought $1,167,750 worth of shares (225,000 units at $5.19), increasing direct ownership by 8% to 2,908,803 units (SEC Form 4)

Amendment: SEC Form SC 13G/A filed by OmniAb Inc.

Amendment: SEC Form SC 13D/A filed by OmniAb Inc.

Director Bertozzi Carolyn R converted options into 17,769 shares, increasing direct ownership by 47% to 55,539 units (SEC Form 4)

Director Love Steven converted options into 13,333 shares (SEC Form 4)

Director Cochran Jennifer R. converted options into 1,896 shares, increasing direct ownership by 2% to 115,274 units (SEC Form 4)

OmniAb Announced Publication Of Peer-Reviewed Paper Titled "Chickens with a Truncated Light Chain Transgene Express Single-Domain H Chain-Only Antibodies" In Journal Of Immunology

OmniAb To Present High-Throughput Single B-cell Screening xPloration Data At The 20th Annual PEGS Boston Summit

Benchmark Reiterates Buy on OmniAb, Maintains $8 Price Target

$OABI Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

RBC Capital Mkts initiated coverage on OmniAb with a new price target

The Benchmark Company initiated coverage on OmniAb with a new price target

Craig Hallum initiated coverage on OmniAb with a new price target

$OABI Leadership Updates

Live Leadership Updates

OmniAb Appoints Steve Love to its Board of Directors

$OABI Press Releases

Fastest customizable press release news feed in the world

OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights

OmniAb to Participate in Two Investor Conferences in November

OmniAb to Report Third Quarter 2024 Financial Results on November 12

Recent Analyst Ratings for
$OABI

$OABI
SEC Filings

$OABI
Financials

$OABI
Insider Purchases

$OABI
Large Ownership Changes

$OABI
Insider Trading

$OABI
Market Insights

$OABI
Analyst Ratings

$OABI
Leadership Updates

$OABI
Press Releases